Skip to main content
Livermore
Livermore
ZHEN

Affinity Asset Advisors, LLC

SEC CIK
0001773195
Latest filing
Aug 13, 2026

Holdings in Q3 2023

Holdings as of Sep 30, 2023, filed Nov 14, 2023. Long positions only; changes compare share counts with Q2 2023.

Institution overview
Positions
69
+7 vs. Q2 2023
Portfolio value
$306.1M
+$52.0M (+20.5%) vs. Q2 2023
Filed
Nov 14, 2023
SEC
Holdings of Affinity Asset Advisors, LLC in Q3 2023
SecurityClassSharesValue% of portfolioShare changeActionHistory
APGEApogee Therapeutics, Inc.COM1,045,110$22.3M7.3%+1,045,110NewHistory
TEVATeva Pharmaceutical Industries LtdSPONSORED ADS2,000,000$20.4M6.7%+400,000+25.0%AddedHistory
CBAYCymaBay Therapeutics, Inc.COM1,129,376$16.8M5.5%+79,258+7.5%AddedHistory
BridgeBio Pharma, Inc.10806XAB8NOTE 2.500% 3/1–$16.4M5.4%–––
CERECerevel Therapeutics Holdings, Inc.COM685,061$15.0M4.9%+135,061+24.6%AddedHistory
ACLXArcellx, Inc.COMMON STOCK400,000$14.4M4.7%+173,725+76.8%AddedHistory
CRNXCrinetics Pharmaceuticals, Inc.COM450,000$13.4M4.4%+450,000NewHistory
MDGLMadrigal Pharmaceuticals, Inc.COM85,000$12.4M4.1%−7,500−8.1%ReducedHistory
ESTAEstablishment Labs Holdings Inc.COM239,108$11.7M3.8%+27,500+13.0%AddedHistory
IMVTImmunovant, Inc.COM300,000$11.5M3.8%+40,000+15.4%AddedHistory
XENEXenon Pharmaceuticals Inc.COM300,438$10.3M3.4%+240,062+397.6%AddedHistory
KURAKura Oncology, Inc.COM856,535$7.81M2.6%−53,782−5.9%ReducedHistory
ATXSAstria Therapeutics, Inc.COM1,000,300$7.46M2.4%+349,425+53.7%AddedHistory
CYTKCytokinetics IncCOM NEW230,366$6.79M2.2%+105,218+84.1%AddedHistory
KRYSKrystal Biotech, Inc.COM57,500$6.67M2.2%+57,500NewHistory
CNTACentessa Pharmaceuticals plcSPONSORED ADS1,018,091$6.59M2.2%+117,368+13.0%AddedHistory
MORFMorphic Holding, Inc.COM270,000$6.19M2.0%+68,113+33.7%AddedHistory
VRNAVerona Pharma plcSPONSORED ADS368,329$6.00M2.0%−79,338−17.7%ReducedHistory
INZYInozyme Pharma, Inc.COM1,379,852$5.80M1.9%+628,056+83.5%AddedHistory
AUTLAutolus Therapeutics plcSPON ADS1,992,466$4.64M1.5%+403,449+25.4%AddedHistory
SVRASavara IncCOM1,150,000$4.35M1.4%+1,150,000NewHistory
ASNDAscendis Pharma A/SSPONSORED ADR46,400$4.34M1.4%−11,360−19.7%ReducedHistory
CLDXCelldex Therapeutics, Inc.COM NEW150,000$4.13M1.3%+62,969+72.4%AddedHistory
AZNAstraZeneca PLCSPONSORED ADR60,000$4.06M1.3%00.0%UnchangedHistory
TNGXTango Therapeutics, Inc.COM350,000$3.94M1.3%+350,000NewHistory
PRTAProthena Corp Public Ltd CoSHS79,214$3.82M1.2%−20,786−20.8%ReducedHistory
MRSNMersana Therapeutics, Inc.COM2,850,000$3.62M1.2%+2,850,000NewHistory
VKTXViking Therapeutics, Inc.COM300,000$3.32M1.1%00.0%UnchangedHistory
SYRESpyre Therapeutics, Inc.COM NEW242,297$2.97M1.0%+46,297+23.6%AddedConverted for a 1-for-25 splitHistory
DVAXDynavax Technologies CorpCOM NEW200,000$2.95M1.0%+200,000NewHistory
MLTXMoonLake ImmunotherapeuticsCLASS A ORD50,000$2.85M0.9%+50,000NewHistory
ALKSAlkermes plc.SHS100,000$2.80M0.9%+100,000NewHistory
KALVKalVista Pharmaceuticals, Inc.COM278,292$2.68M0.9%+100,000+56.1%AddedHistory
MRTXMirati Therapeutics, Inc.COM60,426$2.63M0.9%+60,426NewHistory
IMTXImmatics N.V.SHS200,000$2.32M0.8%−100,000−33.3%ReducedHistory
NUVLNuvalent, Inc.COM50,000$2.30M0.8%+50,000NewHistory
SGENSeagen Inc.COM10,000$2.12M0.7%+10,000NewHistory
LNTHLantheus Holdings, Inc.Stock30,000$2.08M0.7%+30,000NewHistory
NRIXNurix Therapeutics, Inc.COM250,000$1.97M0.6%+150,000+150.0%AddedHistory
ROIVRoivant Sciences Ltd.SHS150,000$1.75M0.6%+150,000NewHistory
TERNTerns Pharmaceuticals, Inc.COM325,000$1.63M0.5%+325,000NewHistory
APLSApellis Pharmaceuticals, Inc.COM40,000$1.52M0.5%+30,000+300.0%AddedHistory
PCVXVaxcyte, Inc.COM25,000$1.27M0.4%+11,077+79.6%AddedHistory
INSPInspire Medical Systems, Inc.COM6,293$1.25M0.4%+6,293NewHistory
NAMSNewAmsterdam Pharma Co N.V.ORDINARY SHARES125,000$1.16M0.4%+25,000+25.0%AddedHistory
TRMLTourmaline Bio, Inc.COM400,000$1.12M0.4%+200,000+100.0%AddedHistory
THRXTheseus Pharmaceuticals, Inc.COM400,726$1.08M0.4%+160,482+66.8%AddedHistory
MISTMilestone Pharmaceuticals Inc.COM335,068$1.04M0.3%+35,000+11.7%AddedHistory
LIANYLianBioSPONSORED ADS672,357$1.00M0.3%−128,319−16.0%ReducedHistory
ADCTADC Therapeutics SASHS1,100,000$986.7K0.3%+500,000+83.3%AddedHistory
IFRXInflaRx N.V.COM325,097$968.8K0.3%+84,897+35.3%AddedHistory
SWTXSpringWorks Therapeutics, Inc.COM41,581$961.4K0.3%−88,419−68.0%ReducedHistory
MIRMMirum Pharmaceuticals, Inc.COM30,000$948.0K0.3%00.0%UnchangedHistory
TVTXTravere Therapeutics, Inc.COM100,000$894.0K0.3%+100,000NewHistory
PODDInsulet CorpStock5,000$797.5K0.3%+5,000NewHistory
BBIOBridgeBio Pharma, Inc.COM30,000$791.1K0.3%−5,133−14.6%ReducedHistory
BHVNBiohaven Ltd.COM30,156$784.4K0.3%+30,156NewHistory
TECXTectonic Therapeutic, Inc.COM500,000$770.0K0.3%+500,000NewHistory
Immatics N.V.N44445117*W EXP 07/01/202187,204$662.7K0.2%00.0%Unchanged–
PBYIPuma Biotechnology, Inc.COM202,349$532.2K0.2%00.0%UnchangedHistory
PMNProMIS Neurosciences Inc.COM265,958$526.7K0.2%+265,958NewHistory
CNTXContext Therapeutics Inc.COM328,817$496.5K0.2%+61,243+22.9%AddedHistory
NUVBNuvation Bio Inc.COM CL A250,000$335.0K0.1%00.0%UnchangedHistory
BCABBioAtla, Inc.COM180,000$306.0K0.1%−145,000−44.6%ReducedHistory
ALDXAldeyra Therapeutics, Inc.COM44,348$296.2K0.1%−105,652−70.4%ReducedHistory
NAMSWNewAmsterdam Pharma Co N.V.*W EXP 11/22/202137,000$260.3K0.1%+100,000+270.3%AddedHistory
NLS Pharmaceutics LtdH57830103SHS200,455$140.3K<0.1%−199,545−49.9%Reduced–
ARAVAravive, Inc.COM346,511$45.7K<0.1%+346,511NewHistory
Rocket Pharmaceuticals, Inc.77313F114*W EXP 09/02/20275,000$7.50K<0.1%00.0%Unchanged–

Options (12)

Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.

Option positions of Affinity Asset Advisors, LLC in Q3 2023
SecurityClassPutsCalls
TEVATeva Pharmaceutical Industries LtdSPONSORED ADS–$11.2M
ARK ETF Tr00214Q302GENOMIC REV ETF$6.96M–
ESTAEstablishment Labs Holdings Inc.COM–$6.87M
ALKSAlkermes plc.SHS–$5.60M
APLSApellis Pharmaceuticals, Inc.COM$4.95M–
IMVTImmunovant, Inc.COM$4.92M–
VKTXViking Therapeutics, Inc.COM$3.68M–
ACRSAclaris Therapeutics, Inc.COM$1.78M–
EYPTEyePoint, Inc.COM NEW$1.24M–
MORFMorphic Holding, Inc.COM$1.15M–
ETNB89bio, Inc.COM–$575.9K
MESOMesoblast LtdSPONS ADR$492.0K–

Sold out since Q2 2023 (15)

Positions held at the end of Q2 2023 that are gone from this filing.

Positions of Affinity Asset Advisors, LLC sold out since Q2 2023
SecurityClassShares in Q2 2023Value in Q2 2023% of portfolio in Q2 2023History
KDNYChinook Therapeutics, Inc.COM321,017$12.3M4.9%History
BIIBBiogen Inc.COM40,000$11.4M4.5%History
Esperion Therapeutics Inc Ne29664WAB1NOTE 4.000%11/1–$3.44M1.4%–
VTYXVentyx Biosciences, Inc.COM100,696$3.30M1.3%History
RETAReata Pharmaceuticals IncCL A29,105$2.97M1.2%History
KYNBKyntra Bio, Inc.COM983,300$2.65M1.0%History
VINCVincerx Pharma, Inc.COM NEW1,492,771$1.94M0.8%History
CABACabaletta Bio, Inc.COM125,000$1.61M0.6%History
Intrexon Corp46122TAA0NOTE 3.500% 7/0–$1.51M0.6%–
WHWKWhitehawk Therapeutics, Inc.COM187,675$1.28M0.5%History
ALPNAlpine Immune Sciences, Inc.COM118,891$1.22M0.5%History
MLYSMineralys Therapeutics, Inc.COM62,500$1.07M0.4%History
AXSMAxsome Therapeutics, Inc.COM12,500$898.3K0.4%History
JSPRJasper Therapeutics, Inc.COM476,948$653.4K0.3%History
VIRVir Biotechnology, Inc.COM20,000$490.6K0.2%History